Apar Kishor Ganti1, Shanmuga P Subbiah2, Anne Kessinger3, Wilson I Gonsalves4, Peter T Silberstein5, Fausto R Loberiza3. 1. Department of Internal Medicine, VA Nebraska Western Iowa Health Care System, Omaha, NE; Division of Oncology/Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE. Electronic address: aganti@unmc.edu. 2. Department of Internal Medicine, VA Nebraska Western Iowa Health Care System, Omaha, NE; Division of Oncology/Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE; Division of Oncology/Hematology, Department of Internal Medicine, Creighton University Medical Center, Omaha, NE. 3. Division of Oncology/Hematology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE. 4. Division of Oncology/Hematology, Department of Internal Medicine, Creighton University Medical Center, Omaha, NE. 5. Department of Internal Medicine, VA Nebraska Western Iowa Health Care System, Omaha, NE; Division of Oncology/Hematology, Department of Internal Medicine, Creighton University Medical Center, Omaha, NE.
Abstract
BACKGROUND: Racial disparities in outcomes of non-small-cell lung cancer (NSCLC) patients in the United States are well documented. A retrospective analysis of patients in the Veterans Affairs Central Cancer Registry was conducted to determine whether similar disparities exist in a population with a single-payer, accessible health care system. PATIENTS AND METHODS: Demographic data of patients diagnosed with NSCLC between January 1995 and February 2009 were analyzed using Kruskal-Wallis test or the χ(2) test. Multivariate Cox proportional hazards regression analysis was used to compare survival among races. RESULTS: Of the 82,414 patients, 98% were male, 82% had a smoking history, and 81% were Caucasian. Caucasian individuals had better prognostic features compared with African-American individuals (stage I/II [24% vs. 21%]; Grade I/II [21% vs. 17%]). A larger proportion of Caucasian compared with African-American individuals received stage-appropriate treatment (surgery for stage I [48% vs. 41%; P < .001]; chemotherapy for stage IV [18% vs. 16%; P = .003]). African-American individuals had a lower risk of mortality compared with Caucasian individuals (hazard ratio, 0.94; 95% confidence interval, 0.92-0.96). CONCLUSION: Although African-American patients had a higher stage and grade of NSCLC, they had a better overall survival than Caucasian patients. In a single-payer system with accessible health care, previously described racial differences in lung cancer outcomes were not observed. Published by Elsevier Inc.
BACKGROUND: Racial disparities in outcomes of non-small-cell lung cancer (NSCLC) patients in the United States are well documented. A retrospective analysis of patients in the Veterans Affairs Central Cancer Registry was conducted to determine whether similar disparities exist in a population with a single-payer, accessible health care system. PATIENTS AND METHODS: Demographic data of patients diagnosed with NSCLC between January 1995 and February 2009 were analyzed using Kruskal-Wallis test or the χ(2) test. Multivariate Cox proportional hazards regression analysis was used to compare survival among races. RESULTS: Of the 82,414 patients, 98% were male, 82% had a smoking history, and 81% were Caucasian. Caucasian individuals had better prognostic features compared with African-American individuals (stage I/II [24% vs. 21%]; Grade I/II [21% vs. 17%]). A larger proportion of Caucasian compared with African-American individuals received stage-appropriate treatment (surgery for stage I [48% vs. 41%; P < .001]; chemotherapy for stage IV [18% vs. 16%; P = .003]). African-American individuals had a lower risk of mortality compared with Caucasian individuals (hazard ratio, 0.94; 95% confidence interval, 0.92-0.96). CONCLUSION: Although African-American patients had a higher stage and grade of NSCLC, they had a better overall survival than Caucasian patients. In a single-payer system with accessible health care, previously described racial differences in lung cancer outcomes were not observed. Published by Elsevier Inc.
Authors: Carissa C Jones; Sarah Fletcher Mercaldo; Jeffrey D Blume; Angela S Wenzlaff; Ann G Schwartz; Heidi Chen; Stephen A Deppen; William S Bush; Dana C Crawford; Stephen J Chanock; William J Blot; Eric L Grogan; Melinda C Aldrich Journal: J Thorac Oncol Date: 2018-06-06 Impact factor: 15.609
Authors: Jill K Schinkel; Stephanie Shao; Shelia H Zahm; Katherine A McGlynn; Craig D Shriver; Kangmin Zhu Journal: Cancer Epidemiol Date: 2016-05-06 Impact factor: 2.984
Authors: Norma E Farrow; Selena J An; Paul J Speicher; David H Harpole; Thomas A D'Amico; Jacob A Klapper; Matthew G Hartwig; Betty C Tong Journal: J Thorac Cardiovasc Surg Date: 2019-11-13 Impact factor: 5.209
Authors: Janis Campbell; Krupa Gandhi; Anne Pate; Amanda Janitz; Amber Anderson; Robin Kinnard; Kai Ding Journal: J Okla State Med Assoc Date: 2016 Jul-Aug
Authors: Kim Peterson; Johanna Anderson; Erin Boundy; Lauren Ferguson; Ellen McCleery; Kallie Waldrip Journal: Am J Public Health Date: 2018-03 Impact factor: 9.308
Authors: Jonathan Pastrana Del Valle; Nathanael R Fillmore; George Molina; Mark Fairweather; Jiping Wang; Thomas E Clancy; Stanley W Ashley; Richard D Urman; Edward E Whang; Jason S Gold Journal: Ann Surg Oncol Date: 2022-01-10 Impact factor: 5.344
Authors: Eduardo R Núñez; Tanner J Caverly; Sanqian Zhang; Mark E Glickman; Shirley X Qian; Jacqueline H Boudreau; Donald R Miller; Renda Soylemez Wiener Journal: Chest Date: 2022-02-26 Impact factor: 10.262
Authors: Eduardo R Núñez; Tanner J Caverly; Sanqian Zhang; Mark E Glickman; Shirley X Qian; Jacqueline H Boudreau; Christopher G Slatore; Donald R Miller; Renda Soylemez Wiener Journal: JAMA Netw Open Date: 2021-07-01